Wyeth reported record financial results for 2006, with net revenue increasing 9% to $20.4 billion and net income growing 14% to $4.2 billion. The company achieved over $1 billion in annual sales for six product franchises. Research and development efforts led to the filing of four new drug applications. Wyeth continues to invest in innovation through its pharmaceutical, biotech, vaccine and consumer healthcare divisions to address unmet medical needs and drive future growth.